Regencell bioscience holdings limited announces closing of initial public offering

Hong kong--(business wire)--regencell bioscience holdings limited (nasdaq:rgc) (“regencell” or the “company”), an early-stage bioscience company that focuses on research, development and commercialization of traditional chinese medicine (“tcm”) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder (“adhd”) and autism spectrum disorder (“asd”), today announced the closing of its initial public offering (the “offering”) of 2,300,000
RGC Ratings Summary
RGC Quant Ranking